Last reviewed · How we verify

NCT06977230

Remote Ischemic Preconditioning in Type 2 Diabetic Patients Undergoing CABG

Recruiting now NA Last updated 18 June 2025
What this trial tests

NA trial testing Remote Ischemic Preconditioning in Diabetes Mellitus in 60 participants. Currently enrolling.

Timeline
26 May 2025
Primary endpoint
30 July 2025
15 September 2025

Quick facts

Lead sponsorMuğla Sıtkı Koçman University
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposeprevention
Enrollment60
Start date26 May 2025
Primary completion30 July 2025
Estimated completion15 September 2025
Sites2 locations across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Muğla Sıtkı Koçman University

Who can join

Adults 45 to 85, any sex, with Diabetes Mellitus or Coronary Artery Bypass. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This randomized, double-blind, prospective clinical trial aims to investigate the effect of remote ischemic preconditioning (RIPC) on myocardial protection in patients with type 2 diabetes mellitus undergoing elective coronary artery bypass graft (CABG) surgery. Perioperative myocardial injury remains a significant concern during CABG, particularly in high-risk patients such as those with diabetes. RIPC is a low-cost, non-invasive intervention that may reduce myocardial damage by enhancing ischemic tolerance through intermittent limb ischemia. Sixty patients aged 40-85 years with type 2 diabetes scheduled for isolated CABG will be randomized to either receive RIPC or standard care. RIPC will be applied through five cycles of upper limb cuff inflation and deflation prior to sternotomy. High-sensitivity troponin T levels will be measured at 24, 48, and 72 hours postoperatively to assess myocardial injury. Secondary outcomes include acute kidney injury (KDIGO classification), maximum vasoactive-inotropic score (VIS) during the first 72 postoperative hours, ICU and hospital length of stay. This study will provide insight into the cardioprotective role of RIPC in diabetic patients undergoing cardiac surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Remote Ischemic Preconditioning

Trials testing the same drug.

Other recruiting trials for Diabetes Mellitus

Currently open trials in the same condition.

Other Muğla Sıtkı Koçman University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06977230.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing